Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
TURP, laser enucleation and vaporization, UroLift, Rezum. Main billing specialty: urology.
Medicare fee-for-service BPH procedures cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 202 | 14,148−8%/yr | −8%/yr | 4.20.9× | 48% | 14,100 in 2030−0.1%/yr |
| Florida | 187 | 13,311−3.9%/yr | −3.9%/yr | 5.91.3× | 45% | 13,300 in 20300%/yr |
| Texas | 150 | 9,762−6.5%/yr | −6.5%/yr | 4.51.0× | 41% | 9,710 in 2030−0.1%/yr |
| New York | 98 | 8,386−6.8%/yr | −6.8%/yr | 4.61.0× | 43% | 8,420 in 2030+0.1%/yr |
| New Jersey | 53 | 6,600−1.2%/yr | −1.2%/yr | 6.31.3× | 53% | 5,800 in 2030−2.1%/yr |
| Ohio | 84 | 6,150−1.9%/yr | −1.9%/yr | 5.51.2× | 21% | 5,630 in 2030−1.5%/yr |
| Arizona | 79 | 6,117−8.2%/yr | −8.2%/yr | 8.21.8× | 55% | 6,220 in 2030+0.3%/yr |
| Illinois | 93 | 5,993−6.1%/yr | −6.1%/yr | 4.30.9× | 36% | 5,880 in 2030−0.3%/yr |
| Pennsylvania | 78 | 5,698−7.3%/yr | −7.3%/yr | 4.20.9× | 31% | 4,890 in 2030−2.5%/yr |
| Georgia | 60 | 5,270−5.6%/yr | −5.6%/yr | 6.11.3× | 42% | 4,930 in 2030−1.1%/yr |
| Maryland | 65 | 4,904−8.2%/yr | −8.2%/yr | 5.51.2× | 82% | 4,770 in 2030−0.5%/yr |
| Tennessee | 62 | 4,487−4.2%/yr | −4.2%/yr | 6.31.4× | 43% | 4,180 in 2030−1.2%/yr |
| Virginia | 64 | 4,475+1.2%/yr | +1.2%/yr | 4.30.9× | 32% | 3,890 in 2030−2.3%/yr |
| North Carolina | 53 | 4,163−9.2%/yr | −9.2%/yr | 4.20.9× | 15% | 3,750 in 2030−1.7%/yr |
| South Carolina | 59 | 3,847−5.5%/yr | −5.5%/yr | 5.61.2× | 23% | 3,310 in 2030−2.5%/yr |
| Indiana | 54 | 3,762−4.3%/yr | −4.3%/yr | 5.31.1× | 17% | 3,750 in 20300%/yr |
| Michigan | 40 | 3,700−3.6%/yr | −3.6%/yr | 4.30.9× | 29% | 3,320 in 2030−1.8%/yr |
| Washington | 49 | 3,507−5.1%/yr | −5.1%/yr | 4.51.0× | 27% | 3,370 in 2030−0.6%/yr |
| Missouri | 44 | 2,933−12%/yr | −12%/yr | 4.71.0× | 20% | 2,710 in 2030−1.3%/yr |
| Colorado | 49 | 2,851−4%/yr | −4%/yr | 5.81.2× | 43% | 2,530 in 2030−2%/yr |
| Massachusetts | 46 | 2,725−3.2%/yr | −3.2%/yr | 2.90.6× | 13% | 2,910 in 2030+1.1%/yr |
| Oklahoma | 41 | 2,246−10%/yr | −10%/yr | 4.61.0× | 36% | 2,140 in 2030−0.8%/yr |
| Wisconsin | 40 | 2,152−11%/yr | −11%/yr | 3.80.8× | 14% | 2,150 in 20300%/yr |
| Mississippi | 29 | 2,122−13%/yr | −13%/yr | 5.61.2× | 48% | 1,630 in 2030−4.3%/yr |
| Kansas | 37 | 2,068−4.1%/yr | −4.1%/yr | 5.11.1× | 37% | 1,920 in 2030−1.3%/yr |
| Oregon | 25 | 1,987−8.3%/yr | −8.3%/yr | 4.71.0× | 44% | 1,720 in 2030−2.4%/yr |
| Louisiana | 22 | 1,850−5.9%/yr | −5.9%/yr | 4.51.0× | 30% | 1,540 in 2030−3.1%/yr |
| Arkansas | 29 | 1,636−4.1%/yr | −4.1%/yr | 4.30.9× | 35% | 1,550 in 2030−0.9%/yr |
| Iowa | 29 | 1,578−7.8%/yr | −7.8%/yr | 3.50.8× | 34% | 1,380 in 2030−2.2%/yr |
| Minnesota | 25 | 1,559−8.7%/yr | −8.7%/yr | 3.40.7× | 14% | 1,980 in 2030+4.1%/yr |
| Kentucky | 16 | 1,515−6.7%/yr | −6.7%/yr | 3.30.7× | 23% | 1,270 in 2030−2.9%/yr |
| Nebraska | 20 | 1,469−17%/yr | −17%/yr | 5.61.2× | 29% | 1,250 in 2030−2.7%/yr |
| Alabama | 14 | 1,324−10%/yr | −10%/yr | 3.00.6× | 18% | 940 in 2030−5.5%/yr |
| Connecticut | 20 | 1,316+0.2%/yr | +0.2%/yr | 3.90.8× | 19% | 1,290 in 2030−0.3%/yr |
| Utah | 29 | 1,113−15%/yr | −15%/yr | 5.11.1× | 14% | 1,080 in 2030−0.5%/yr |
| Idaho | 17 | 1,020−1.6%/yr | −1.6%/yr | 5.01.1× | 38% | 1,180 in 2030+2.4%/yr |
| Nevada | 22 | 901−13%/yr | −13%/yr | 3.10.7× | 60% | 1,050 in 2030+2.5%/yr |
| New Hampshire | 11 | 730−2.7%/yr | −2.7%/yr | 3.20.7× | 25% | 880 in 2030+3.1%/yr |
| Delaware | 11 | 729−4.8%/yr | −4.8%/yr | 4.20.9× | 45% | 790 in 2030+1.4%/yr |
| Montana | 12 | 679−16%/yr | −16%/yr | 3.60.8× | 7% | 580 in 2030−2.5%/yr |
| South Dakota | 12 | 636+8.3%/yr | +8.3%/yr | 4.91.0× | 4% | 580 in 2030−1.6%/yr |
| West Virginia | 11 | 613−15%/yr | −15%/yr | 2.90.6× | 0% | 420 in 2030−6.2%/yr |
| Alaska | 6 | 477+20%/yr | +20%/yr | 4.00.8× | 59% | 640 in 2030+5%/yr |
| New Mexico | 10 | 453−21%/yr | −21%/yr | 2.00.4× | 7% | 410 in 2030−1.6%/yr |
| District of Columbia | 6 | 425−0.5%/yr | −0.5%/yr | 6.71.4× | 58% | 390 in 2030−1.5%/yr |
| Maine | 6 | 406−1.3%/yr | −1.3%/yr | 2.60.5× | 0% | 340 in 2030−2.8%/yr |
| Rhode Island | 5 | 342+2.1%/yr | +2.1%/yr | 3.70.8× | 20% | 270 in 2030−3.7%/yr |
| North Dakota | 10 | 315−10%/yr | −10%/yr | 3.10.7× | 15% | 340 in 2030+1.1%/yr |
| Hawaii | 5 | 293−11%/yr | −11%/yr | 2.30.5× | 43% | 390 in 2030+5%/yr |
| Vermont | 3 | 213−6.2%/yr | −6.2%/yr | 1.90.4× | 0% | 320 in 2030+7.2%/yr |
| Wyoming | 4 | 186−7.9%/yr | −7.9%/yr | 1.70.4× | 39% | 240 in 2030+4.1%/yr |
Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 28 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 10 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Neotract | 7 |
| Proverum | 6 |
| Urotronic | 5 |
| Boston Scientific | 2 |
| Medi-Tate | 2 |
| Prodeon Medical | 2 |
| Biosphere Medical | 1 |
| Microvention | 1 |
| Srs Medical | 1 |
| Zenflow | 1 |
Product codes: MER (stent, urethral, prostatic, permanent or semi-permanent), NOY (agents, embolic, for treatment of benign prostatic hyperplasia), NZC (stent, urethral, prostatic, semi-permanent), OEJ (transurethral electrosurgical unit, benign prostatic hyperplasia), OEK (water-induced thermotherapy system, benign prostatic hyperplasia), OEL (laser, benign prostatic hyperplasia), PEW (implantable transprostatic tissue retractor system), QKA (temporarily-placed urethral opening system for symptoms of benign prostatic hyperplasia), QXB (drug coated prostatic dilation catheter for benign prostatic hyperplasia). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved −9 pts since 2019, to 38%.
The 10 busiest do 31% of the cases CMS names in California; 96 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Kidney stone management | 3,401 | 159,938−1.4%/yr | −1.4%/yr | 172,300 in 2030+1.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 906 | 83,637−1.3%/yr | −1.3%/yr | 95,100 in 2030+2.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 1,058 | 73,050−1.4%/yr | −1.4%/yr | 83,900 in 2030+2.3%/yr |
| Prostatectomy & nephrectomy | 592 | 37,032−1.1%/yr | −1.1%/yr | 45,600 in 2030+3.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 11 companies reported engagement with surgeons in the covered states worth $3.9M in consulting, speaking, meals and travel tied to these products, about $1,759 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.